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We experienced a patient with angioimmunoblastic T-cell lymphoma (AITL) without Epstein–Barr virus-
positive B (EBV-B) cells at initial presentation who progressed to AITL with expansion of EBV-B cells at
relapse. Based on the results of repeated biopsy, the patient was successfully treated with rituximab in
combination with chemotherapy at relapse. A repeat biopsy may be necessary to determine the optimum
therapeutic strategy at relapse, particularly for patients with suspected expansion of B cell and/or EBV-B
cells. Although a recent report found no signiﬁcant prognostic advantage of rituximab, it is one of the
active drugs for selected patients with AITL.
& 2013 Elsevier Ltd.Open access under CC BY-NC-ND license.Case report
In May 2010, a 63-year-old Japanese male was referred to our
hospital with skin rash, fever, general fatigue, bilateral pharyngitis,
multiple superﬁcial lymphadenopathies, and weight loss of 10 kg in
2 months. His white blood cell count was 9.8109/L, of which 1.5%
were atypical lymphoid cells. His hemoglobin level was 9.7 g/dL and
his platelet count was 79109/L. His serum albumin, lactate dehy-
drogenase, and C-reactive protein levels were 24 g/L, 363 IU/L, and
11.54 mg/dL, respectively. The results of other liver and renal function
tests were o1.5 times the upper limits of normal. Although his
serum immunoglobulin (Ig) G, IgA, and IgM levels were 3359, 246,
and 252 mg/dL, respectively, there was no evidence of monoclonal
gammopathy. The Coombs test was positive, and tests for human
immunodeﬁciency virus and human T-lymphotropic virus type I
were negative. Epstein–Barr virus (EBV) antibody to viral capsid
antigen (EBVVCA) IgM was negative but EBVVCA IgG was positive.
EBV antibody to nuclear antigen (EBNA) IgG was also positive. As
positron emission tomography (PET)/computed tomography (CT)
images revealed multiple superﬁcial, intra-abdominal, and: +81 0724 69 7929.
oto).
-NC-ND license.mesenteric lymphadenopathies that were accompanied by hepatos-
plenomegaly, a pharyngeal biopsy was performed. Microscopically,
the biopsied tissue contained atypical, neoplastic CD3-positive T cells
admixed with CD20-negative and EBV-encoded small RNA (EBER)-
negative B cells (Fig. 1a). Based on these ﬁndings, the patient was
diagnosed with peripheral T-cell lymphoma, not otherwise speciﬁed.
Therefore, he was treated with six cycles of chemotherapy consisting
of cyclophosphamide, adriamycin, vincristine, and prednisolone
(CHOP). After chemotherapy, his blood test results had improved
and there was no evidence of hepatosplenomegaly or lymphadeno-
pathy on CT images, nor was there any abnormal accumulation of
[18F]-ﬂuorodeoxyglucose (18F FDG) on PET scans. The patient
achieved complete remission (CR) in November 2010. However,
1 month later, disease recurrence was conﬁrmed. Thereafter, he
received low-dose etoposide, prednisolone, and cyclophosphamide,
followed by low-dose methotrexate (MTX) and cyclosporine (CsA).
Despite this regimen, we found enlargement of his lymph nodes,
particularly of his left axillary lymph nodes, as their diameter
was 410 cm at this time (Fig. 2a). His serum monoclonal IgM level
had also increased to 5445 mg/dL. The patient's Eastern Cooperative
Oncology Group performance status (PS) was 4. A repeat biopsy of
the left axillary lymph node was performed in August 2011. A large
number of non-neoplastic, CD20- and EBER-positive B cells and
neoplastic CD3-positive T cells were found in the biopsy specimen
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Fig. 1. (a) Images of the pharyngeal biopsy samples taken at the initial presentation. Abnormal lymphoid cells were found in hematoxylin and eosin-stained biopsy samples.
These abnormal lymphoid cells were positive for CD3 and negative for CD20 and EBER and (b) images of the left axillary lymph node biopsy samples. The lymph node
contained a large number of neoplastic CD3 positive T-cells admixed with non-neoplastic, CD20 and EBER positive B-cells.
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munoblastic T-cell lymphoma (AITL). Based on the diagnosis of AITL
with proliferation of CD20- and EBER-positive B cells, the patient was
treated with rituximab monotherapy. Although the lymph node did
not shrink rapidly, his serum IgM level decreased to 4200 mg/dL
following two cycles of once-weekly rituximab. He was then treated
with four cycles of CHOP combined with rituximab (R-CHOP). The
enlarged lymph nodes almost disappeared after this treatment, and
his serum IgM level decreased to 800 mg/dL. Abnormal 18F FDG
accumulationwas not detected on PET scans, although a small (2 cm)
lymph node was detected in the left axillary lymph node on a CT scan
taken after four cycles of R-CHOP in January 2012 (Fig. 2b). The
patient's condition improved dramatically, reaching a PS of 0 at this
time. He ultimately completed six cycles of R-CHOP, and CR was
maintained for 6 months until relapse in June 2012.Advani et al. reported that CsA was associated with good
overall and durable responses.1 Although the mechanism remains
unclear, CsA may inhibit the function of T cells, including their
production of cytokines involved in the progression of AITL.
Consequently, immunosuppressive therapies might exacerbate
EBV infection and the occurrence of secondary cancer. Targeted
therapies, such as rituximab, might have a potential role in the
treatment of AITL. Rituximab may eradicate EBV-B cells and
activated B cells, and may prevent the progression to AITL.
However, the authors of a multicenter phase II trial conducted
by the Groupe d' Etude des Lymphomes de l' Adulte concluded that
R-CHOP did not improve prognosis as compared with standard
CHOP.2 EBV infection and proliferation of EBV-B cells are usually
detected in patients with AITL, especially in advanced stages of the
disease.3 These clinical features are thought to occur secondary to
Fig. 2. (a) CT scan of the patient taken at relapse of AITL and (b) CT scan of the
patient taken after completion of the R-CHOP regimen.
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load was correlated with disease progression and B cell clonality.3
Delfau-Laure et al. reported that a higher EBV load tended to be
associated with a shorter progression-free survival, although the
presence of EBV copies in peripheral blood mononclear cells
(PBMC) was not associated with the response to R-CHOP.2
We should discuss whether the presence of EBV-DNA in PBMC is
more useful than repeated lymph node biopsy for determining the
optimum salvage strategy at the time of relapse. EBV is generally
detected at the initial diagnosis of AITL in most patients. Therefore,
the detection of EBV-DNA in PBMC, alone, may be insufﬁcient to
determine the treatment starategy at relapse. If EBV-DNA in PBMC is
negative or if its level is low at initial diagnosis of AITL, and if a higherEBV load is detected in these patients at relapse, these observations
might indicate EBV infection/reactivation and proliferation of EBV-B
cells, consistent with disease progression. However, EBV-positive
lymphoproliferative disorder or diffuse large B-cell lymphoma were
reported in some patients with AITL.5,6 Therefore, although repeated
lymph node biopsy is invasive, it should be considered for patients
with AITL who have high EBV loads or if expansion of B cells and/or
EBV-B cells is suspected at relapse. The results of such tests may also
help clinicians to differentiate between AITL and other EBV-positive
disorders.
Our patient with AITL, without expansion of EBV-B cells at
initial presentation, was treated with CHOP, followed by low-dose
MTX and CsA upon early relapse after the CHOP regimen. The
proliferation of EBV-B cells was found in a repeat lymph node
biopsy taken at relapse following MTX and CsA therapy. Therefore,
we treated the patient with R-CHOP, which was very effective.
Although a repeat lymph node biopsy is rarely performed after
deﬁnitive diagnosis of AITL, we strongly recommend that it is
performed in selected patients with AITL.Contribution
All authors contributed to the writing and preparation of the
manuscript.
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